Clinical trial · Observational
Recommendations for the Treatment of Children With Acute Lymphoblastic Leukemia in the GFAOP
NCT04794296CI-TRIAL-00104316LALGFA2019recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The LALGFA2019 Recommendations redefine the standard risk criteria and propose to introduce anthracycline induction in so-called high-risk forms (LAL line T and LAL line B with leukocytosis greater than or equal to 50 G/L or in children less than 1 year of age or more than 10 years of age) as well as Endoxan and Methotrexate in high dose consolidation.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Childhood ALL | Childhood Acute Lymphoblastic Leukemia | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (5)
- measure
- Feasibility of these recommendations
- timeFrame
- This can be initially reviewed after the first 2 years and will be evaluated at the end for the community.
- description
- Availability of drugs. This is part of the project as we are working with Low or low to Middle Income countries.
- measure
- Correct application of therapeutic recommendations
- timeFrame
- 5 weeks
- description
- Availability of drugs and adherence to protocol: Some centers may at times have to find locally the chemiotherapy for application of the protocol. The capacity of the units to do this is alos being studied. By looking at why treatment was not given. Was it because of lack of discipline regarding the attendance at the units for treatment, transport, accommodation, or medication not available ?
- measure
- Complete Remission Rate (CR) close to 85% after induction
- timeFrame
- J 34 or j42 post start of induction treatment for all children studied.
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: Children 0 to 18 ALL first diagnosis No prior chemotherapy Cytology FAB L1 or L2 \- Exclusion Criteria: ALL L3 (Burkitt) ALL previously treated with chemotherapy Trisomy 21
References
Publications (0)
Data not yet available
No reference posted for this study.